viewRevive Therapeutics

Revive Therapeutics submits IND application to the FDA for potential coronavirus treatment Bucillamine

The application is for a Phase 3 confirmatory study for Bucillamine as a potential treatment in COVID-19

Revive Therapeutics -
Phase 3 is currently slated to begin in the third quarter of 2020

Revive Therapeutics Ltd (CSE:RVV) (OTCMKTS:RVVTF) has submitted its Investigational New Drug (IND) application to the US Food and Drug Administration for its Phase 3 study of potential coronavirus treatment Bucillamine, it said Tuesday.

The Toronto-based company believes Bucillamine has the potential, via increasing glutathione activity and other anti-inflammatory activity, to lessen the destructive effects of COVID-19 infection in the lungs.

Once approval is received, Toronto-based Revive will begin a randomized, double-blind and placebo-controlled study of Bucillamine on patients with mild to moderate COVID-19 symptoms. The study is currently slated to begin in the third quarter of 2020.

READ: Revive Therapeutics holds pre-CTA meeting with Health Canada for Bucillamine to treat COVID-19 patients

“We are very pleased in achieving this major milestone of filing our IND for a Phase 3 confirmatory study to evaluate Bucillamine in the treatment of patients with mild-moderate COVID-19, which was based on the recommendation from the US FDA from our pre-IND meeting earlier this year,” Michael Frank, Revive’s CEO said in a statement.

Bucillamine has a strong clinical history as a treatment for rheumatoid arthritis. Since Revive conducted a Phase 2 trial for gout in the past, it has strong supporting documentation for the FDA for a potential Phase 3 study.

The primary objective of Phase 3 is to compare frequency of hospitalization and mortality in patients with mild-moderate COVID-19 receiving Bucillamine therapy with those receiving placebo. 

The Phase 3 study will be a multicenter, randomized, double-blind, placebo-controlled study of Bucillamine, or placebo in patients with mild-to-moderate COVID-19. Symptomatic patients will initially be randomized 1:1:1 to receive Bucillamine 300 mg/day, Bucillamine 600 mg/day, or a placebo.

“We are preparing plans for initiating the Phase 3 study upon the IND becoming active by the US FDA and we look forward to advancing Bucillamine as a potential new treatment option for patients with a confirmed diagnosis of COVID-19 globally.”

Revive recently held a Pre-Clinical Trial Application meeting with Health Canada to evaluate the potential of a clinical study of Bucillamine in Canada.

Shares of Revive jumped 13.7% higher to close at C$0.29 in Canada and 11.8% over the counter at US$0.21.

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

Quick facts: Revive Therapeutics

Price: 0.6 CAD

Market: CSE
Market Cap: $142.07 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Revive Therapeutics named herein, including the promotion by the Company of Revive Therapeutics in any Content on the Site, the Company...


Revive Therapeutics: Analyst sees 'substantial upside potential' as key...

Proactive Research analyst Ed Stacey says Revive Therapeutics (CSE:RVV)(OTCQB:RVVTF) is a speciality life sciences company focussed on repurposing drugs for rare and infectious diseases and has a pipeline of of three main platforms. One of them is Bucillamine (BUC) which is a medication with a...

on 06/30/2020

2 min read